Trial Profile
Clinical study of EPZ 5676 in patients with acute myeloid leukaemia with MLL-PTD genetic alterations
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Jul 2015
Price :
$35
*
At a glance
- Drugs Pinometostat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Epizyme
- 07 May 2014 This trial is recruiting patients into the expansion part of the trial. Data are expected to be reported in the second half of 2014, according to an Epizyme media release.
- 06 Nov 2013 New trial record